469 related articles for article (PubMed ID: 26494964)
41. Association of genetic variants with non-alcoholic fatty liver disease in an urban Sri Lankan community.
Kasturiratne A; Akiyama K; Niriella MA; Takeuchi F; Isono M; Dassanayake AS; de Silva AP; Wickremasinghe RA; Kato N; de Silva HJ
Liver Int; 2015 Feb; 35(2):676-9. PubMed ID: 24947803
[No Abstract] [Full Text] [Related]
42. Genetic Markers Predisposing to Nonalcoholic Steatohepatitis.
Sohal A; Chaudhry H; Kowdley KV
Clin Liver Dis; 2023 May; 27(2):333-352. PubMed ID: 37024211
[TBL] [Abstract][Full Text] [Related]
43. The Effects of Metabolic Surgery on Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Clanton J; Subichin M
Surg Clin North Am; 2016 Aug; 96(4):703-15. PubMed ID: 27473796
[TBL] [Abstract][Full Text] [Related]
44. Progress in the search for circulating biomarkers of nonalcoholic fatty liver disease.
Amacher DE
Biomarkers; 2014 Nov; 19(7):541-52. PubMed ID: 25189636
[TBL] [Abstract][Full Text] [Related]
45. Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy.
Wei JL; Leung JC; Loong TC; Wong GL; Yeung DK; Chan RS; Chan HL; Chim AM; Woo J; Chu WC; Wong VW
Am J Gastroenterol; 2015 Sep; 110(9):1306-14; quiz 1315. PubMed ID: 26215532
[TBL] [Abstract][Full Text] [Related]
46. Association of nonalcoholic fatty liver disease and liver cancer.
Schulz PO; Ferreira FG; Nascimento Mde F; Vieira A; Ribeiro MA; David AI; Szutan LA
World J Gastroenterol; 2015 Jan; 21(3):913-8. PubMed ID: 25624725
[TBL] [Abstract][Full Text] [Related]
47. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
48. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.
Satapathy SK; Sanyal AJ
Semin Liver Dis; 2015 Aug; 35(3):221-35. PubMed ID: 26378640
[TBL] [Abstract][Full Text] [Related]
49. Genetic polymorphisms and oxidative stress in non-alcoholic steatohepatitis (NASH): A mini review.
Oliveira CP; Stefano JT
Clin Res Hepatol Gastroenterol; 2015 Sep; 39 Suppl 1():S35-40. PubMed ID: 26160475
[TBL] [Abstract][Full Text] [Related]
50. Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander.
Vanni E; Marengo A; Mezzabotta L; Bugianesi E
Semin Liver Dis; 2015 Aug; 35(3):236-49. PubMed ID: 26378641
[TBL] [Abstract][Full Text] [Related]
51. The Genetics of Clinical Liver Diseases: Insight into the
Zhang X; Liu S; Dong Q; Xin Y; Xuan S
J Clin Transl Hepatol; 2018 Sep; 6(3):326-331. PubMed ID: 30271746
[TBL] [Abstract][Full Text] [Related]
52. Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
Krawczyk M; Stachowska E; Milkiewicz P; Lammert F; Milkiewicz M
Digestion; 2016; 93(2):139-48. PubMed ID: 26745555
[TBL] [Abstract][Full Text] [Related]
53. Systems biology approaches for studying the pathogenesis of non-alcoholic fatty liver disease.
Fisher CP; Kierzek AM; Plant NJ; Moore JB
World J Gastroenterol; 2014 Nov; 20(41):15070-8. PubMed ID: 25386055
[TBL] [Abstract][Full Text] [Related]
54. TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism.
Coppola N; Rosa Z; Cirillo G; Stanzione M; Macera M; Boemio A; Grandone A; Pisaturo M; Marrone A; Adinolfi LE; Sagnelli E; Miraglia del Giudice E
Liver Int; 2015 Aug; 35(8):1959-63. PubMed ID: 25581573
[TBL] [Abstract][Full Text] [Related]
55. Lipoprotein metabolism in liver diseases.
Perez-Matos MC; Sandhu B; Bonder A; Jiang ZG
Curr Opin Lipidol; 2019 Feb; 30(1):30-36. PubMed ID: 30550414
[TBL] [Abstract][Full Text] [Related]
56. Genetics of non-alcoholic fatty liver disease: From susceptibility and nutrient interactions to management.
Ravi Kanth VV; Sasikala M; Sharma M; Rao PN; Reddy DN
World J Hepatol; 2016 Jul; 8(20):827-37. PubMed ID: 27458502
[TBL] [Abstract][Full Text] [Related]
57. Human Genetics to Identify Therapeutic Targets for NAFLD: Challenges and Opportunities.
Du X; DeForest N; Majithia AR
Front Endocrinol (Lausanne); 2021; 12():777075. PubMed ID: 34950105
[TBL] [Abstract][Full Text] [Related]
58. Unique Genetic Features of Lean NAFLD: A Review of Mechanisms and Clinical Implications.
Tidwell J; Wu GY
J Clin Transl Hepatol; 2024 Jan; 12(1):70-78. PubMed ID: 38250459
[TBL] [Abstract][Full Text] [Related]
59. Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease.
Wood KL; Miller MH; Dillon JF
BMJ Open Gastroenterol; 2015; 2(1):e000019. PubMed ID: 26462272
[TBL] [Abstract][Full Text] [Related]
60. Genetic Insights for Drug Development in NAFLD.
Eslam M; George J
Trends Pharmacol Sci; 2019 Jul; 40(7):506-516. PubMed ID: 31160124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
